147 related articles for article (PubMed ID: 29380366)
1. Biodegradable nanoparticles as theranostics of ovarian cancer: an overview.
Chaurasiya S; Mishra V
J Pharm Pharmacol; 2018 Apr; 70(4):435-449. PubMed ID: 29380366
[TBL] [Abstract][Full Text] [Related]
2. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable inorganic nanoparticles: an opportunity for improved cancer therapy?
Li L; Liu H
Nanomedicine (Lond); 2017 May; 12(9):959-961. PubMed ID: 28440705
[No Abstract] [Full Text] [Related]
4. Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.
Xie Z; Su Y; Kim GB; Selvi E; Ma C; Aragon-Sanabria V; Hsieh JT; Dong C; Yang J
Small; 2017 Mar; 13(10):. PubMed ID: 28026115
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Nanoparticles in Cancer Theranostics.
Gobbo OL; Sjaastad K; Radomski MW; Volkov Y; Prina-Mello A
Theranostics; 2015; 5(11):1249-63. PubMed ID: 26379790
[TBL] [Abstract][Full Text] [Related]
6. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging.
Elzoghby AO; Hemasa AL; Freag MS
J Control Release; 2016 Dec; 243():303-322. PubMed ID: 27794493
[TBL] [Abstract][Full Text] [Related]
7. Theranostic Nanoparticles for Pancreatic Cancer Treatment.
Jaidev LR; Chede LS; Kandikattu HK
Endocr Metab Immune Disord Drug Targets; 2021; 21(2):203-214. PubMed ID: 32416712
[TBL] [Abstract][Full Text] [Related]
8. Echogenic Glycol Chitosan Nanoparticles for Ultrasound-Triggered Cancer Theranostics.
Min HS; You DG; Son S; Jeon S; Park JH; Lee S; Kwon IC; Kim K
Theranostics; 2015; 5(12):1402-18. PubMed ID: 26681985
[TBL] [Abstract][Full Text] [Related]
9. Cancer theranostic applications of lipid-based nanoparticles.
Tang WL; Tang WH; Li SD
Drug Discov Today; 2018 May; 23(5):1159-1166. PubMed ID: 29660478
[TBL] [Abstract][Full Text] [Related]
10. Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.
Di Lorenzo G; Ricci G; Severini GM; Romano F; Biffi S
Theranostics; 2018; 8(16):4279-4294. PubMed ID: 30214620
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable Inorganic Nanoparticles for Cancer Theranostics: Insights into the Degradation Behavior.
Zhou H; Ge J; Miao Q; Zhu R; Wen L; Zeng J; Gao M
Bioconjug Chem; 2020 Feb; 31(2):315-331. PubMed ID: 31765561
[TBL] [Abstract][Full Text] [Related]
12. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Nanostructures for Ovarian Cancer.
Navyatha B; Nara S
Crit Rev Ther Drug Carrier Syst; 2019; 36(4):305-371. PubMed ID: 31679190
[TBL] [Abstract][Full Text] [Related]
14. Photoacoustic-based nanomedicine for cancer diagnosis and therapy.
Sim C; Kim H; Moon H; Lee H; Chang JH; Kim H
J Control Release; 2015 Apr; 203():118-25. PubMed ID: 25701310
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Vangara KK; Liu JL; Palakurthi S
Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
[TBL] [Abstract][Full Text] [Related]
16. Current state and prospects of the phytosynthesized colloidal gold nanoparticles and their applications in cancer theranostics.
Ovais M; Raza A; Naz S; Islam NU; Khalil AT; Ali S; Khan MA; Shinwari ZK
Appl Microbiol Biotechnol; 2017 May; 101(9):3551-3565. PubMed ID: 28382454
[TBL] [Abstract][Full Text] [Related]
17. Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics.
Lin CJ; Kuan CH; Wang LW; Wu HC; Chen Y; Chang CW; Huang RY; Wang TW
Biomaterials; 2016 Jun; 90():12-26. PubMed ID: 26974704
[TBL] [Abstract][Full Text] [Related]
18. Biocompatible polymersomes-based cancer theranostics: Towards multifunctional nanomedicine.
Mohammadi M; Ramezani M; Abnous K; Alibolandi M
Int J Pharm; 2017 Mar; 519(1-2):287-303. PubMed ID: 28115259
[TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide-based theranostic nanoparticles in cancer therapy.
Shahbazi R; Ozpolat B; Ulubayram K
Nanomedicine (Lond); 2016 May; 11(10):1287-308. PubMed ID: 27102380
[TBL] [Abstract][Full Text] [Related]
20. Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery.
Huang P; Liu J; Wang W; Zhang Y; Zhao F; Kong D; Liu J; Dong A
Acta Biomater; 2016 Aug; 40():263-272. PubMed ID: 26607767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
